|
Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis Clinical research trials and Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis. Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis clinical trial. Human subjects frequently get the finest healthcare available for their Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis  Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis
Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis
For Condition: stereotyped behavior,Mental Retardation
Status: Recruiting
Sponsor(s): National Institute of Child Health and Human Development (NICHD) , University of Florida
Synopsis: OBJECTIVES: I. Determine differences between persons with repetitive behavior disorders and matched controls on measures of motor control relevant to basal ganglia pathophysiology. II. Determine the efficacy of bromocriptine, a dopamine agonist, in the treatment of stereotyped behavior and related behavior disorders. III. Determine the efficacy of sertraline hydrochloride, a selective serotonin uptake inhibitor, in the treatment of repetitive behavior disorders. IV. Identify behavioral, environmental, and biological variables with differential drug treatment response.
Details: PROTOCOL OUTLINE: Motor slowness (bradykinesia) and motor control are tested in repetitive behavior disorder patients and matched controls. Group differences reflecting alterations in basal ganglia dopamine function are compared. Behavioral assessments are conducted on each patient by trained observers. Assessments are taken at baseline and during the maintenance phase of drug treatment described below. The efficacy of bromocriptine in the treatment of stereotypy and self-injury is determined in a randomized, double blind, placebo controlled, crossover study extending over 20 weeks. Cohorts of 6 to 8 patients first enter into a single blind placebo phase, followed by double blind treatment with placebo or bromocriptine. The crossover manipulation entails a titration phase, a maintenance phase, then a final single blind placebo condition. The same experimental design is used to determine the efficacy of sertraline or placebo in the treatment of stereotypy and concomitant self injury and compulsions. Duration of study is 26 weeks.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/55 Years
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of mental retardation - High rate of stereotyped behavior, such as concomitant self-injurious and compulsive behaviors - No diagnosis of tardive dyskinesia or akathisia --Prior/Concurrent Therapy-- - No exposure to neuroleptics within 6 months prior to study --Patient Characteristics-- - Age: 18 to 55 - Hematopoietic: (for bromocriptine and sertraline treatments) No history of anemia No clinically significant hematologic disease - Hepatic: (for bromocriptine and sertraline treatments) No history of hepatic abnormalities No clinically significant liver disease - Renal: (for bromocriptine and sertraline treatments) No history of renal abnormalities No clinically significant renal disease - Cardiovascular: (for bromocriptine and sertraline treatments) No history of hypertension No clinically significant cardiac disease - Other: No history of seizure within 4 months prior to study (for bromocriptine and sertraline treatments) No history of sensitivity to ergot alkaloids (for bromocriptine treatment) No sensitivity to serotonin uptake inhibitors (for sertraline treatment) No patients with sensory deficits (for motor function assessments)
Total Enrollment: 40
Location and Contact Information:
Overall Study Official:
MarkLewis, Study Chair, University of Florida
Western Carolina Center *Recruiting*
Morganton, North Carolina, 28655
United States
Recruiting James Bodfish 828-438-6518
Additional Information:
Study ID Numbers: 199/11754; UF-63394
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004300
Other Stereotyped Behavior Studies:
1. Self-Injury: Diagnosis and Treatment
2. Study of Smith-Lemli-Opitz Syndrome
3. Genetic Aspects of Neurologic and Psychiatric Disorders
4. Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis
5. Evaluation of Patients with Unresolved Chromosome Abnormalities
Related Studies:
Other stereotyped behavior Clinical Trials
Other North Carolina Clinical Trials
Other Morganton Clinical Trials
Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis
|
|
|
|
|
|
|
|
